# Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

> **NCT06279871** · PHASE3 · COMPLETED · sponsor: **Arcturus Therapeutics, Inc.** · enrollment: 1514 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** ARCT-2303
- **BIOLOGICAL:** Influenza vaccine
- **BIOLOGICAL:** Influenza vaccine, adjuvanted
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06279871
- **Lead sponsor:** Arcturus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-27
- **Primary completion:** 2024-10-09
- **Final completion:** 2024-11-21
- **Target enrollment:** 1514 (ACTUAL)
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06279871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06279871, "Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06279871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*